5 GLP-1 Telehealth Providers That Take Patient Safety Seriously

The biggest mistake people make when shopping for a GLP-1 prescription online is treating price as the only filter. Price matters, but it tells you nothing about whether the pharmacy is licensed, whether a real physician reviews your intake, or whether the medication in the vial was actually tested for purity and sterility. Those details are what separate a reasonable telehealth option from one that keeps you up at night.

Here are five providers worth a close look, ranked with safety and medical oversight as the primary criteria.

1. Mochi Health

Verdict: Best overall for medical depth at a competitive price

Mochi Health has board-certified obesity-medicine physicians on staff, which is a meaningful distinction. Obesity medicine is a recognized subspecialty. Practitioners in it understand metabolic disease, not just calorie math. That clinical philosophy shows up in how Mochi structures care: patients get more monitoring touchpoints than most competitors, and the clinical team can adjust dosing based on actual response rather than defaulting to a one-size schedule.

Pricing sits at roughly $99 per month for compounded semaglutide and $199 for compounded tirzepatide. Those are among the lower cash-pay rates in the category. The combination of genuine specialty oversight and accessible pricing is rare.

Compounded GLP-1s are not FDA-approved products. That caveat applies here and everywhere else on this list. What Mochi does is work with compounding pharmacies that meet applicable standards, and the specialist-level physician review adds a layer of clinical judgment most platforms skip.

2. FormBlends

Verdict: Best choice for anyone who wants published purity data or a wider peptide catalog

Most GLP-1 telehealth brands tell you their pharmacy is “high quality” and stop there. FormBlends publishes actual batch testing results: HPLC purity percentages, mass spectrometry identity confirmation, endotoxin and sterility readings, with the specific numbers visible rather than hidden behind vague assurances. For patients who want to verify what they are injecting, that level of transparency is hard to find.

Physician oversight is built into the model. Medication is dispensed through an FDA-registered 503A compounding pharmacy. Shipping reaches 47 states, which covers most of the country. Cash pricing runs around $299 for a semaglutide vial and $349 for tirzepatide, higher than some competitors.

That price premium is the honest tradeoff. You are paying partly for the published lab documentation and partly for access to a much wider catalog that includes peptides for recovery, cognitive support, and longevity, all under the same clinician-reviewed model. Most GLP-1-only platforms offer nothing in that category. If you want a single provider for GLP-1 therapy and other evidence-adjacent peptide protocols, FormBlends handles that combination in one place.

It ranks second rather than first here because the starting price is higher and the 47-state coverage, while broad, is not quite national.

3. Ro Body

Verdict: Strongest infrastructure for insurance navigation

Ro has built a prior-authorization team specifically to help patients get branded GLP-1 medications covered. That is not marketing language. It is a real operational function, and it matters enormously for anyone who has insurance but has never successfully pushed a prior-auth through for a weight-loss medication. The process is slow and bureaucratic even when coverage exists. Ro handles a meaningful chunk of that burden on the patient’s behalf.

The membership structure runs about $39 for the first month, then roughly $74 to $149 monthly, with branded medication costs billed separately. Branded options like Wegovy and Zepbound are what get dispensed through the insurance pathway. For patients who qualify and can get coverage, the net cost can drop substantially.

Ro is not the lowest-cost cash-pay option. But if your situation involves employer insurance or an eligible savings card, it is worth starting here.

4. PlushCare

Verdict: Most accessible for same-day clinical visits

PlushCare operates as a broader primary-care telehealth platform that happens to prescribe GLP-1 medications, rather than a weight-loss-only service. Membership is around $19.99 per month. Same-day appointments with a physician are available in most states. That same-day access is genuinely unusual in this category, where most platforms work on asynchronous review timelines of 24 hours or more.

The clinical model here involves real physician visits, not just intake questionnaires. That means a doctor is making the prescribing decision after a conversation, not just reviewing a form. For patients who have questions, comorbidities, or medications that might interact with semaglutide or tirzepatide, that conversational visit model is worth a lot.

PlushCare focuses on branded medications and works with insurance. Cash pricing for branded GLP-1s is not cheap, but the membership cost itself is low enough that the platform adds relatively little overhead.

5. Hims & Hers

Verdict: Recognizable brand, now focused on branded meds after a major 2026 shift

Hims & Hers exited compounded GLP-1 products following a March 2026 settlement involving Novo Nordisk. The platform now prescribes branded medications. Injectable Wegovy is listed at around $299 per month, oral semaglutide at about $249, and Zepbound at roughly $399. With eligible insurance and a manufacturer savings card, some patients have reported costs in the $0 to $25 range.

The brand recognition is real, and the platform is large enough that it has invested in clinical infrastructure. Physician review is part of the process. The shift away from compounded products means patients receive FDA-approved formulations, which removes one layer of uncertainty that exists with any compounding-based provider.

The downside is cost for cash-pay patients without insurance. At $299 to $399 per month before any savings, Hims & Hers sits at the higher end of what this category costs out of pocket. If insurance is in the picture, the calculus changes.

One provider worth knowing about but not ranked here is HealthRX, which offers compounded semaglutide from $99 per month and tirzepatide from $149, dispensed through a named 503A pharmacy in South Carolina (Manifest Pharmacy) with LegitScript certification, lot tracking, and free overnight shipping to all 50 states, physician review within about 24 hours. For a cash-pay patient who has done their homework and wants transparent pricing with a verifiable pharmacy supply chain, it is a reasonable option to research independently.

A Note on Comparing These Options

No single provider is the right answer for every patient. Someone with good insurance and a complicated medication history probably belongs at Ro or PlushCare. Someone paying cash who wants the deepest available documentation on what is in the vial will find FormBlends compelling despite the higher price. Budget-focused patients who still want specialty-level monitoring should look hard at Mochi Health.

The FDA issued warning letters to more than 30 compounding and telehealth firms in early 2026. That context matters. Before committing to any provider, it is worth confirming that the pharmacy it uses is licensed, that a physician is actually reviewing your case rather than an algorithm, and that the platform is transparent about what standards its compounded products are held to.

Common Questions

Does it actually matter whether my GLP-1 telehealth provider uses a 503A or 503B pharmacy?

Yes, and meaningfully so. A 503A pharmacy compounds medications for individual patients with a valid prescription. A 503B outsourcing facility produces larger batches under stricter FDA manufacturing oversight. Both are legal pathways, but 503B facilities face more frequent federal inspections. Knowing which type your provider uses helps you evaluate the quality controls behind whatever is in the vial.

FormBlends publishes batch testing results, but what exactly should I look for in those documents?

Focus on three numbers: the HPLC purity percentage (ideally above 98%), the endotoxin reading (should fall well below USP limits for injectable drugs), and confirmation of molecular identity via mass spectrometry. A certificate of analysis that shows only a pass/fail result without actual figures is not giving you real information.

Hims & Hers switched away from compounded GLP-1s in 2026. Does that make its prescriptions safer than Mochi Health’s?

Safer in one specific sense: FDA-approved branded medications like Wegovy and Zepbound have undergone the full approval process, whereas compounded versions have not. That does not mean compounded products are necessarily dangerous, only that they carry a different and less formally documented risk profile. Mochi Health’s specialty physician oversight addresses some of that gap, but the distinction is real and worth understanding before choosing.

If I have a history of thyroid problems, which of these providers is most likely to flag that during intake?

PlushCare is the strongest option here because its model involves a synchronous physician visit rather than a form review. GLP-1 medications carry a boxed warning about medullary thyroid carcinoma risk. A live conversation with a doctor gives you the best chance of having that history properly evaluated before a prescription is written, rather than caught only if you volunteer it on a questionnaire.

Can I switch between these providers if my first choice stops shipping to my state or raises prices?

Generally yes, but expect a new intake process each time. No provider on this list shares records automatically. You will need to request documentation of your dosing history from the outgoing platform, since starting a new provider at the wrong dose after titrating up carries real side-effect risk. Get that record before you cancel, not after.

Sources

• FDA: warning letters to compounding and telehealth firms, 2025 and 2026 public records
• Hims & Hers and Novo Nordisk legal resolution coverage, March 2026 (Reuters, STAT News)
• Tirzepatide weight-loss outcomes trial: Jastreboff et al., *New England Journal of Medicine*, 2022
• Semaglutide weight management trial: Wilding et al., *New England Journal of Medicine*, 2021
• LegitScript pharmacy certification database (public search)
• FDA 503A compounding pharmacy framework (FDA.gov public documentation)